My focus of research is in prostate cancer which can be divided into two areas: 1. Biomarker discovery and validation: Using the critical mass and bioresource facilities of the Prostate Cancer Research Consortium (of which I am the lead PI) the group undertake to address clinically relevant questions to identify and validate biomarkers for grade and stage of prostate cancer which will inform appropriate treatment strategies. 2. Understanding the mechanisms of resistances to therapy of advanced disease. We have established models of resistance to androgen ablation therapy and chemoresistance and using genechip and bioinformatice strategies have identified central transcription factors which represent novel sites for therapeutic manipulation which form the bases of your research directions as well as the role of EMT in apoptotic resistance. As a translational biologist based at the Conway Institute I utilise latest technologies to study the cellular and molecular pathways of prostate cancer. I use this knowledge to address clinically relevant questions via my clinical collaborators as part of the Prostate Cancer Research Consortium and iPROSPECT. These studies have identified novel biomarkers for patient stratification into appropriate treatment groups and targets for therapeutic manipulation which we are validating with our International collaborators as part of the Movember Global Action Plan and ToPCaP.